Literature DB >> 30336532

Prognostic Value of ALT, AST, and AAR in Hepatocellular Carcinoma with B-Type Hepatitis-Associated Cirrhosis after Radical Hepatectomy.

Li Zhou, Shao-Bin Wang, Shu-Guang Chen, Qiang Qu, Jing-An Rui.   

Abstract

BACKGROUND: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and AST to ALT ratio (AAR) were shown to be associated with prognosis in some groups of hepatocellular carcinoma (HCC). However, their clinicopathologic and prognostic roles in HCC patients with B-type hepatitis-associated cirrhosis (HBAC) have not been comprehensively investigated. The present study aimed to address the issues.
METHODS: A total of 125 patients with HCC and HBAC after radical hepatectomy were included. The correlations of ALT, AST, and AAR with clinicopathologic parameters, overall/recurrence-free survival, overall/early recurrence, and post-recurrence survival were evaluated using univariate and multivariate analyses.
RESULTS: ALT and AST, which positively correlated with each other, had significant relationships with tumornode-metastasis (TNM) stage and Edmondson-Steiner grade. In univariate analyses, ALT and AST were predictive for early recurrence, overall and recurrence-free survival, while ALT and AST was associated with overall recurrence and post-recurrence survival, respectively. However, only AST was marginally significant in multivariate tests for early recurrence and post-recurrence survival. As for AAR, no significant prognostic relevance was found.
CONCLUSIONS: Our data suggest that ALT and AST, but not AAR, might be potential predictors of post-resectional outcome in HCC with HBAC. These effects might depend on their associations with crucial clinicopathologic variables.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30336532     DOI: 10.7754/Clin.Lab.2018.180532

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  8 in total

1.  Comparison of the prognosis of BCLC stage A ruptured hepatocellular carcinoma patients after undergoing transarterial chemoembolization (TACE) or hepatectomy: a propensity score-matched landmark analysis.

Authors:  Feng Xia; Qiao Zhang; Xiaoping Chen; Bixiang Zhang; Elijah Ndhlovu; Mingyu Zhang; Peng Zhu
Journal:  Surg Endosc       Date:  2022-08-03       Impact factor: 3.453

2.  Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib.

Authors:  Lei Zhang; Wei Xia; Zhi-Ping Yan; Jun-Hui Sun; Bin-Yan Zhong; Zhong-Heng Hou; Min-Jie Yang; Guan-Hui Zhou; Wan-Sheng Wang; Xing-Yu Zhao; Jun-Ming Jian; Peng Huang; Rui Zhang; Shen Zhang; Jia-Yi Zhang; Zhi Li; Xiao-Li Zhu; Xin Gao; Cai-Fang Ni
Journal:  Front Oncol       Date:  2020-09-30       Impact factor: 6.244

3.  MRI-based radiomics model for preoperative prediction of 5-year survival in patients with hepatocellular carcinoma.

Authors:  Zhao-Hai Wang; Wei-Hu Wang; Xiao-Hang Wang; Liu-Hua Long; Yong Cui; Angela Y Jia; Xiang-Gao Zhu; Hong-Zhi Wang; Zhi Wang; Chong-Ming Zhan
Journal:  Br J Cancer       Date:  2020-01-15       Impact factor: 7.640

4.  Transarterial Chemoembolization Combined With Endoscopic Therapy Is Beneficial for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices.

Authors:  Ziwen Tao; Yuying Ruan; Zhi Peng; Kai Zhang; Yanjing Gao
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

5.  Exosomal microRNA-618 derived from mesenchymal stem cells attenuate the progression of hepatic fibrosis by targeting Smad4.

Authors:  Chao Sun; Cuicui Shi; Xiaoyan Duan; Yi Zhang; Baocan Wang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

6.  Nomogram for the Preoperative Prediction of the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma.

Authors:  Yuying Shan; Xi Yu; Yong Yang; Jiannan Sun; Shengdong Wu; Shuqi Mao; Caide Lu
Journal:  J Hepatocell Carcinoma       Date:  2022-08-10

7.  Machine learning model for the prediction of prostate cancer in patients with low prostate-specific antigen levels: A multicenter retrospective analysis.

Authors:  Xiaobin Deng; Tianyu Li; Linjian Mo; Fubo Wang; Jin Ji; Xing He; Bashir Hussein Mohamud; Swadhin Pradhan; Jiwen Cheng
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

8.  Integration of Inflammation-Immune Factors to Build Prognostic Model Predictive of Prognosis and Minimal Residual Disease for Hepatocellular Carcinoma.

Authors:  Xin Xu; Ao Huang; De-Zhen Guo; Yu-Peng Wang; Shi-Yu Zhang; Jia-Yan Yan; Xin-Yu Wang; Ya Cao; Jia Fan; Jian Zhou; Xiu-Tao Fu; Ying-Hong Shi
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.